Who are Omecamtiv Mecarbil (OM)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Camzyos, TNX-103.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/omecamtiv-mecarbil-om.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Omecamtiv Mecarbil (OM) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Omecamtiv Mecarbil (OM) (Omecamtiv Mecarbil (OM)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cardiac myosin activator. Area: Cardiovascular.

phase 3 Cardiac myosin activator Cardiac myosin Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Omecamtiv Mecarbil (OM) (Omecamtiv Mecarbil (OM)) — Cytokinetics. Omecamtiv mecarbil is a cardiac myosin activator that directly enhances the force of heart muscle contraction by increasing the number of myosin heads that generate force during systole.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Omecamtiv Mecarbil (OM) TARGET	Omecamtiv Mecarbil (OM)	Cytokinetics	phase 3	Cardiac myosin activator	Cardiac myosin
Camzyos	MAVACAMTEN	Bristol-Myers Squibb	marketed	Cardiac Myosin Inhibitor [EPC]	cardiac myosin	2022-01-01
TNX-103	TNX-103	Tenax Therapeutics, Inc.	phase 3	Cardiac myosin inhibitor	Cardiac myosin

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cardiac myosin activator class)

Cytokinetics · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Omecamtiv Mecarbil (OM) — Competitive Intelligence Brief. https://druglandscape.com/ci/omecamtiv-mecarbil-om. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab